We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters to the Editor |

Deceptive Research—Reply

Jon-Kar Zubieta, MD, PhD
Arch Gen Psychiatry. 2008;65(10):1226. doi:10.1001/archpsyc.65.10.1226.
Text Size: A A A
Published online


In reply

We appreciate the commentary by Dr Miller regarding the use of deception in placebo research. The recent study by Scott and collaborators1 was designed to avoid deceptive statements while still obtaining clinically relevant data on the neurobiology of placebo effects. The design used was developed after extensive consultation and input from the investigational review board at our institution and the ethics specialists at the board. It consisted of the use of both active and inactive drug administrations in a parallel design (subjects could receive one or the other, but not both). The informed consent specifically described that the subjects could receive either an inactive or active drug. Furthermore, the adverse effects described in the consent form were those corresponding to the active drug. Perhaps the point of confusion resides on the phrasing used in page 222 of the article, in the “Experimental Design” subsection of the “Methods” section, “Actual pharmacological agents were not administered in these studies,” when it should have read “Actual pharmacological agents were not administered to these subjects” instead. The data contained in this article only describe the responses to the placebo intervention and not those to the active drug.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.